Cat. No. 2916
Chemical Name: (αR,βR)-β-(Cyclopentylmethyl)-N-hydrox
Biological ActivityPotent, collagenase-selective MMP inhibitor (Ki values are 3.0, 3.4, 4.4, 59, 154 and 527 nM for MMP-1, MMP-13, MMP-8, MMP-9, MMP-2 and MMP-3 respectively). Inhibits cartilage breakdown in vitro and in vivo and displays antiarthritic activity. Orally active.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Brewster et al (1998) Ro 32-3555, an orally active collagenase selective inhibitor, prevents structural damage in the SRT/ORT mouse model of osteoarthritis. Arthrit.Rheumat. 41 1639.
Broadhurst et al (1997) Design and synthesis of the cartilage protective agent (CPA, Ro32-3555). Bioorg.Med.Chem.Letts. 7 2299.
Lewis et al (1997) Ro 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo. Br.J.Pharmacol. 121 540. PMID: 9179398.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for Ro 32-3555 include:
Przybyla et al (2013) Matrix remodeling maintains embryonic stem cell self-renewal by activating Stat3. Stem Cells 31 1097. PMID: 23404867.
Do you know of a great paper that uses Ro 32-3555 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Ro 32-3555, supplier, Ro32-3555, MMP, matrix, metalloproteinase, metalloprotease, collagenase, potent, specific, selective, MMP-1, MMP-13, MMP-8, proteases, proteineases, Tocris Bioscience, Matrix Metalloprotease Inhibitor products
Find multiple products by catalog number
New Products in this Area
Potent 20S proteasome inhibitorDiprotin A
Dipeptidyl peptidase IV (DPP-IV) inhibitorAcein
High affinity angiotensin-converting enzyme (ACE) ligandTMI 1
Adam 17 (TACE) and MMP inhibitor; orally bioavailableRitonavir
HIV-1 and HIV-2 protease inhibitor
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.